about
National Athletic Trainers' Association position statement: management of asthma in athletes.Desensitization of ovalbumin-sensitized mice by repeated co-administrations of di-(2-ethylhexyl) phthalate and ovalbumin.A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacyIs interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE.A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities.The SCHOOL of nature: III. From mechanistic understanding to novel therapiesIntralymphatic immunotherapyProduction of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis.Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies.The regulation of allergy and asthma.New therapeutic strategies targeting transmembrane signal transduction in the immune system.Peptide immunotherapy for childhood allergy - addressing translational challenges.IgE-mediated cow's milk allergy in children.In contrast to specific B cells, human basophils are unaffected by the toxic activity of an allergen toxin due to lack of internalization of immunoglobulin E-bound allergen.Changes of serum cytokines after the long term immunotherapy with Japanese hop pollen extracts.Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production.
P2860
Q28769235-66DC0542-806A-4816-BC58-EE0F0F4580D7Q30878073-2E3F9CD2-C360-477B-90BC-42D8003408C9Q34442836-44474D96-AFD0-4DB1-85F9-BBA5BB38F2C1Q34537688-D7A4412D-4CDD-462B-B607-81E648512912Q34588997-6C709EB0-4173-4DFF-AA0E-97AA0D6DE8A8Q34619705-FCB95AB4-86E4-42C5-9EE0-AD5FA7041CD3Q35155423-3609FD01-6FD4-4C86-8BF2-FA5683722900Q36025631-2F1A6252-D622-4A12-A866-0481F517D44AQ36327394-A56A3289-B6C0-4BE9-833A-E3F15869B057Q36563540-04A27E10-8AD3-44F5-AB68-391F14587AC5Q37762389-670A4D38-AE4C-43CA-96D9-D8484A8070FDQ37992746-92626C34-1277-4C0A-8129-0920D67A5925Q38030874-DB152AC9-AE92-4A78-B594-0B14E0CA4FD1Q40289297-1167B78A-D795-4939-83CE-0E05ED12F5C0Q40467319-98B0FF84-D2CC-4720-818F-AACD227B78F6Q40511372-E9D4DADE-132F-4127-9161-B74044274574Q40744033-174275CD-195F-42D7-BAC1-8826DBFC2D06Q46961926-565A760B-BF13-4B70-A70E-58697CEAB299
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Immunotherapy: 1999-2004.
@ast
Immunotherapy: 1999-2004.
@en
type
label
Immunotherapy: 1999-2004.
@ast
Immunotherapy: 1999-2004.
@en
prefLabel
Immunotherapy: 1999-2004.
@ast
Immunotherapy: 1999-2004.
@en
P1476
Immunotherapy: 1999-2004.
@en
P2093
Philip S Norman
P304
1013-23; quiz 1024
P356
10.1016/J.JACI.2004.03.020
P407
P577
2004-06-01T00:00:00Z